The rising incidence, disease awareness, and promising emerging therapies in the pipeline by key players such as Athersys, BioMarck Pharmaceuticals, Faron Pharmaceuticals, Humanigen, Mesoblast Limited, Roche Pharma AG, and others shall propel the Acute Respiratory Distress Syndrome (ARDS) market size further during the forecast period.
DelveInsight’s Acute Respiratory Distress Syndrome Market Insights report provides a comprehensive understanding of current treatment practices, emerging drugs, Acute Respiratory Distress Syndrome market share of individual therapies, and current and forecasted Acute Respiratory Distress Syndrome market size from 2018 to 2030, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Highlights from the Acute Respiratory Distress Syndrome Market Report
- As per DelveInsight’s estimates, the Acute Respiratory Distress Syndrome (ARDS) market size was 709.61 million in 2020 and is expected to increase with a substantial CAGR in the 7MM during the forecast period.
- Key pharma companies working proactively in the Acute Respiratory Distress Syndrome therapeutic market include Athersys, BioMarck Pharmaceuticals, Faron Pharmaceuticals, Humanigen, Mesoblast Limited, Roche Pharma AG, Apeptico Forschung und Entwicklung GmbH, NeuroRx/Relief Therapeutics, Incyte Corporation, Vanda Pharmaceuticals Inc, Mesoblast Limited, and others.
- Key Acute Respiratory Distress Syndrome therapies in the pipeline include Traumakine, BIO-11006, MultiStem, Solnatide, Lenzilumab, Tocilizumab (TCZ), Aviptadil, Ruxolitinib, Tradipitant, Remestemcel-L, and many more.
- It is anticipated that the ARDS market size is predicted to expand significantly during the forecast period due to the introduction of novel therapies, and it is anticipated to grow at a substantial rate over the study period.
Discover more about therapies set to grab major Acute Respiratory Distress Syndrome market share @ Acute Respiratory Distress Syndrome Market Landscape
Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome is a life-threatening condition that affects critically ill people and progresses quickly. The most severe complication of ARDS is fluid leakage into the lungs, which makes breathing difficult or impossible. The ARDS causes are classified as direct or indirect lung injuries. Direct lung injuries include pneumonia, aspiration, trauma, and others. In contrast, indirect lung injuries include pancreatic inflammation, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The symptoms of ARDS include shortness of breath, cough, and fever. In some cases, fast heart rates and rapid breathing have also been reported. Patients with ARDS may experience chest pain, particularly during inhalation, and some may experience bluish colouring of the nails and lips due to severely reduced levels of oxygen in the blood.
Acute Respiratory Distress Syndrome Epidemiology Segmentation
As per DelveInsight, the total Acute Respiratory Distress Syndrome incident population in the 7MM was over 887K, with the US accounting for the maximum number of cases in 2020.
Among EU5 countries, Germany had the highest ARDS incident population while Spain had the lowest in 2020.
The ARDS Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Total Incident Population of ARDS
- Severity-Specific Incident Population of ARDS
- Incident Population of ARDS by Risk Factors
Download report to understand which factors are guiding epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiological Insights
Acute Respiratory Distress Syndrome Market
Despite decades of research, Acute Respiratory Distress Syndrome treatment options are limited. The mainstay of management remains supportive care with mechanical ventilation. There are only a few ARDS treatments available. Other treatment options for patients that develop ARDS include supplemental oxygen, prone positioning, the use of paralytics, fluid management, and a technique known as positive end-expiratory pressure (PEEP) to help push fluid out of air sacs. These are used in addition to ongoing treatment for the original disease or injury. As people with ARDS are less able to fight infections in their lungs, they are more likely to develop bacterial pneumonia. Antibiotics are used to treat infections. Additionally, supportive care, such as intravenous fluids or food may be required.
Furthermore, the current Acute Respiratory Distress Syndrome pipeline includes therapies such as Traumakine (Faron Pharmaceuticals), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico Forschung und Entwicklung GmbH), PB1046 (PhaseBio Pharmaceuticals), and others. Apart from the above-mentioned therapies, Lenzilumab, tocilizumab (TCZ), aviptadil, ruxolitinib, tradipitant, and remestemcel-L are the other pipeline therapies that are expected to enter the market in the forecasted period and will be targeting COVID-19 associated ARDS. The launch of these therapies will positively impact the global Acute Respiratory Distress Syndrome market.
Learn more about the treatment options @ Acute Respiratory Distress Syndrome Market Analysis
Acute Respiratory Distress Syndrome Market: Drivers and Barriers
The factors that are driving the ARDS market include the increase in ARDS incidence and increasing R&D activities by key pharma companies to improve the treatment landscape. Furthermore, the non-competitive landscape of the ARDS market is also boosting market growth.
On the contrary, lack of awareness about the disease, misdiagnosis of ARDS, failure of trials for ARDS are among the factors that are restricting the growth of the market. In addition, the poor mechanical ventilation for ARDS management is also restraining the ARDS market growth.
Scope of the Acute Respiratory Distress Syndrome Market Report
- Study Period: 2018-30
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key ARDS Companies: Athersys, BioMarck Pharmaceuticals, Faron Pharmaceuticals, Humanigen, Mesoblast Limited, Roche Pharma AG, Apeptico Forschung und Entwicklung GmbH, NeuroRx/Relief Therapeutics, Incyte Corporation, Vanda Pharmaceuticals Inc, Mesoblast Limited, and others
- Key ARDS Pipeline Therapies: Traumakine, BIO-11006, MultiStem, Solnatide, Lenzilumab, Tocilizumab (TCZ), Aviptadil, Ruxolitinib, Tradipitant, Remestemcel-L, and others.
- Therapeutic Assessment: Acute Respiratory Distress Syndrome off label and emerging therapies
- Market Dynamics: Acute Respiratory Distress Syndrome market drivers and barriers
- Key Cross Competition
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- Case Studies
- KOL’s Views
- Analyst’s Views
- Market Access and Reimbursement Scenario
Get in touch with our Business executive @ Acute Respiratory Distress Syndrome Market Landscape Analysis
Table of Contents
| 1. | Key Insights |
| 2. | Executive Summary |
| 3. | Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance |
| 4. | Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview |
| 5. | Case Reports |
| 6. | Epidemiology and Patient Population |
| 7. | 7MM Epidemiology Analysis |
| 8. | Treatment Algorithm, Current Treatment, and Medical Practices |
| 9. | Proposed Guidelines for ARDS |
| 10. | Unmet Needs |
| 11. | Off-Label Therapies for ARDS |
| 12. | Emerging Therapies |
| 13. | COVID-19 associated with ARDS: Emerging Drugs |
| 14. | Discontinued Products |
| 15. | Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis |
| 16. | Attribute Analysis |
| 17. | Key Emerging Therapies: Market Forecast Assumptions |
| 18. | 7MM Market Outlook |
| 19. | Access and Reimbursement |
| 20. | Market Drivers |
| 21. | Market Barriers |
| 22. | SWOT Analysis |
| 23. | Appendix |
| 24. | DelveInsight Capabilities |
| 25. | Disclaimer |
| 26. | About DelveInsight |
Related Reports
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market
DelveInsight’s “Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, historical and forecasted epidemiology as well as the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market trends in the 7MM.
DelveInsight’s “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acute Lung Injury, historical and forecasted epidemiology as well as the Acute Lung Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Acute Pulmonary Embolism Market
DelveInsight’s “Acute Pulmonary Embolism- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acute Pulmonary Embolism, historical and forecasted epidemiology as well as the Acute Pulmonary Embolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Respiratory Distress Syndrome Market
DelveInsight’s “Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Respiratory Distress Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Respiratory Syncytial Virus (RSV) Market
DelveInsight’s “Respiratory syncytial virus (RSV) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Respiratory syncytial virus (RSV), historical and forecasted epidemiology as well as the Respiratory syncytial virus (RSV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Neonatal Respiratory Distress Syndrome Pipeline
“Neonatal respiratory distress syndrome Pipeline Insight, 2022” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neonatal respiratory distress syndrome market.
Airway Management Devices Market
DelveInsight’s Airway Management Devices Market Insights, Competitive Landscape, and Market Forecast–2026 report deliver an in-depth understanding of the market and Competitive Landscape analysis. Key players involved in this market include Smiths Medical PLC, Narang Medical Limited, Intersurgical Ltd., Teleflex Incorporated, Stryker Corporation, Medtronic PLC, Dilon Technologies® Inc., Ambu A/S, Medline Industries, LP, ConvaTec Inc., KARL STORZ Endoscopy-America, Inc., Flexicare (Group) Limited, and others.
Latest Healthcare Blogs
Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers
Major Drug Decision for Cardiovascular Diseases to Watch Through 2022
Top 7 Wearable Technology Trends to Watch in 2022
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get in touch with our team to get more detailed insights on how the MedTech Market is expected to evolve in the coming years and to formulate innovative business solutions, at Healthcare Due Diligence Services
Contact Us
Shruti Thakur
+1(919)321-6187